This method was shown to be robust, rapid and sensitive which is a prerequisite for conducting in vivo pharmacokinetic studies.
The paper is titled, "Determination of (-)-epigallocatechin-3-gallate octaacetate and its metabolites in plasma of rats for pharmacokinetic study by ultra-performance-liquid-chromatography coupled to quadrupole-time-of-flight-mass-spectrometry" has been published in Frontiers in Pharmacology which can be downloaded at the following website address: https: //pubmed.ncbi.nlm.nih.gov/36304154/.
Pro-EGCG is a novel small molecule designed for oral administration as a potential non-hormonal based treatment for Endometriosis.
The endometriosis condition is a painful disorder where the endometrial tissue grows outside the uterus, potentially affecting ovaries, fallopian tubes and pelvis tissue, in severe cases affecting fertility.
It has been estimated that endometriosis affects c. 10% of reproductive age women and girls according to the World Health Organisation.
Aptorum Group Ltd. (NASDAQ: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications), autoimmune and infectious diseases.
Aptorum has completed two phase I clinical trials for its ALS-4 and orphan drug designated SACT-1 (Neuroblastoma) small molecule drugs and commercializing its NLS-2 NativusWell nutraceutical (menopause).
The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and the co-development and ongoing clinical validation of its novel molecular-based rapid pathogen identification and detection diagnostics technology with Singapore's Agency for Science, Technology and Research.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer